INTRODUCTION AND OBJECTIVES: Renal medullary carcinoma (RMC) is a rare renal neoplasm accounting for less than 1% of all renal cell carcinomas. RMC, which frequently occurs in young African Americans with sickle cell trait, is an aggressive and lethal cancer with a median overall survival of about 13 months. Recent studies identified the biallelic loss of SMARCB1, a subunit of the SWI/SNF chromatin remodeling complex, as a characteristic feature of RMC tumors. Other reports suggest that the presence of vinculin-anaplastic lymphoma kinase (VCL-ALK) fusion without SMARCB1 loss may represent an RMC variant. We hypothesize that in addition to these alterations, novel driver mutations are present and may become potential targets for treatment. To test this hypothesis, we carried out whole exome sequencing of RMC tumor specimens.
INTRODUCTION AND OBJECTIVES: Large molecular and genomic studies have shown that clear-cell renal cell carcinomas (RCC) share common genomic alterations such as loss of chromosome 3p and VHL gene mutations. However, some clear-cell RCCs do not show these alterations and instead have hotspot mutations in the ELOC gene (aka. TCEB1 -Ch8q21.11). The ELOC gene product is known to bind to the VHL-complex and aid in the ubiquitination/degradation of hypoxiainducible factor-1a. Hotspot mutations in ELOC seem to lead to a 'VHLlike' tumor development mechanism. Previous reports have hypothesized that these tumors may have a more indolent course, however, adequate follow-up was lacking.
METHODS: We performed next-generation sequencing of 468 cancer-associated genes on kidney tumor samples from 524 patients (MSK-IMPACT gene panel, mean coverage¼500x). Patients with ELOC mutations were identified and their medical records were reviewed. Two experienced genitourinary pathologists performed pathological review and immunohistochemical staining of the samples. Clinical and pathological variables, copy number alterations and mutation profiles were analyzed.
RESULTS: Sequencing analysis identified a total of 4 tumors with ELOC mutations. All of them had hotspot mutations Y79C (figure 1) and were VHL and PBRM1 wild type (figure 2). Copy number analysis demonstrated loss of heterozygosity on chromosome 8, and absence of the signature 3p loss. During the follow-up period (median 50.3 months), 1 patient died (6.6%) and 2 developed metastasis (13.3%). The deceased patient also had a TP53 (R248W) hotspot mutation and a SETD2 splice-site mutation (X2477).
CONCLUSIONS: ELOC-mutated RCC seems to be a distinct entity with specific genomic and morphological alterations. Previous reports suggested that these tumors might be more indolent, however, longer clinical follow-up was needed to assess their aggressiveness. We provide evidence that some of these patients present with more aggressive disease.
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PD46-05 INTRA-TUMOR MOLECULAR HETEROGENEITY OF CLEAR CELL RENAL CELL CARCINOMA SEEMS TO CONTRIBUTE TO THE DIVERSITY OF RESPONSE TO TARGETED THERAPIES
Baoan Hong*, Yong Yang, Sheng Guo, Qixiang Li, Ning Zhang, Kan Gong, Beijing, China, People's Republic of INTRODUCTION AND OBJECTIVES: Inter-and intra-tumor molecular heterogeneity is increasingly recognized in clear cell renal cell carcinoma (ccRCC). It could, in part, explain the diversity of responses to targeted therapies and the varied clinical outcomes observed for histologically similar tumors. The present study aimed to examine intra-tumor molecular heterogeneity in primary and metastatic ccRCC tissues and their responses to targeted therapies.
METHODS: A ccRCC patient with multiple metastases received radical nephrectomy and resection of the metastatic tumor in chest wall. Meanwhile, the specimens were implanted into immunedeficient mice to establish Patient-Derived Xenografts (PDXs), with KI2367 derived from primary tumor and KI2368 from metastasis. KI2367 and KI2368 was transcriptome sequenced and treated with Sorafenib, Sunitinib, Axitinib, combined Sorafenib/Sunitinib, or alternating therapy of Sorafenib/ Sunitinib.
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